# Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

> clinical trial · VERIFIED · 2026-07-08

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT01810913

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.